EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Philip Young, Omar Elghawy iD, Joseph Mock, Emmett Wynter, Ryan D Gentzler, Linda W Martin, Wendy Novicoff iD, Richard Hall iD

Current Oncology · 2024

DOI: 10.3390/curroncol31010017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Philip Young und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA 22903, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Opioid-Related Disorders. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICI) have significantly improved outcomes in advanced non-small cell lung cancer (NSCLC). We evaluated the effect of opioid use on outcomes in patients receiving ICI either alone or with chemotherapy. We conducted a retrospective review of 209 patients with advanced NSCLC who received an ICI at the University of Virginia between 1 February 2015 and 1 January 2020. We performed univariate and multivariate analyses to evaluate the impact of opioid use on duration of therapy (DOT) and overall survival (OS). Patients with no or low opioid use (n = 172) had a median DOT of 12.2 months (95% CI: 6.9–17.4) compared to 1.9 months (95% CI: 1.8–2.0) for those with high opioid use (n = 37, HR 0.26 95% CI: 0.17–0.40, p < 0.001). Patients with no or low opioid use had a median OS of 22.6 months (95% CI: 14.8–30.4) compared to 3.8 months (95% CI: 2.7–4.9) for those with high opioid use (HR 0.26 95% CI: 0.17–0.40 p < 0.001). High opioid use was associated with a shorter DOT and worse OS. This difference remained significant when accounting for possible confounding variables. These data warrant investigation of possible mechanistic interactions between opioids, tumor progression, and ICIs, as well as prospective evaluation of opioid-sparing pain management strategies, where possible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsOpioid-Related DisordersHumansAnalgesics, OpioidImmune Checkpoint InhibitorsDuration of Therapy

Stichwörter der Autor:innen

duration of therapyimmune checkpoint inhibitorsnon-small cell lung canceropioidsoverall survival

Substanzen

Analgesics, OpioidImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA 22903, USA.
  • School of Medicine, University of Virginia, Charlottesville, VA 22903, USA.
  • Department of Medicine, University of Virginia, Charlottesville, VA 22903, USA.
  • Department of Surgery, Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, VA 22903, USA.
  • Department of Public Health Sciences and Orthopedic Surgery, University of Virginia, Charlottesville, VA 22903, USA.

ORCID-Profile: Omar Elghawy, Wendy Novicoff, Richard Hall

Zitieren

APA

Young, P., Elghawy, O., Mock, J., Wynter, E., Gentzler, R. D., Martin, L. W., Novicoff, W., & Hall, R. (2024). Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Current Oncology. https://doi.org/10.3390/curroncol31010017

Vancouver

Young P, Elghawy O, Mock J, Wynter E, Gentzler RD, Martin LW, et al. Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Current Oncology. 2024. doi:10.3390/curroncol31010017

BibTeX
@article{Young2024,
  author = {Young, Philip and Elghawy, Omar and Mock, Joseph and Wynter, Emmett and Gentzler, Ryan D and Martin, Linda W and Novicoff, Wendy and Hall, Richard},
  title = {Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31010017}
}
Kostenlos starten →